| PubMed ID |
|
25319867 |
Publish Date |
|
2014 Nov |
| Journal |
|
Nat Rev Cancer |
Species |
|
|
| Disease Type |
|
|
Technology |
|
|
| Title |
|
Translational biology of osteosarcoma. |
| Authors |
|
Kansara M, Teng MW, Smyth MJ, Thomas DM |
| Affiliation |
|
Research Division, Peter MacCallum Cancer Centre, Melbourne, 3002, Victoria, Australia |
| Chromothripsis Definition |
|
Close-by breakpoints: NA
Copy number states: NA
Fragments random joining: NA |
| Abstract |
|
For the past 30 years, improvements in the survival of patients with osteosarcoma have been mostly incremental. Despite evidence of genomic instability and a high frequency of chromothripsis and kataegis, osteosarcomas carry few recurrent targetable mutations, and trials of targeted agents have been generally disappointing. Bone has a highly specialized immune environment and many immune signalling pathways are important in bone homeostasis. The success of the innate immune stimulant mifamurtide in the adjuvant treatment of non-metastatic osteosarcoma suggests that newer immune-based treatments, such as immune checkpoint inhibitors, may substantially improve disease outcome. |
|
